267 related articles for article (PubMed ID: 31222627)
1. From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia.
Yilmaz M; Daver N
Drugs; 2019 Jul; 79(11):1177-1186. PubMed ID: 31222627
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
3. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR; Bullinger L; Rücker FG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
5. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
6. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
7. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
8. [Novel therapies in AML and their resistance mechanisms].
Takahashi K
Rinsho Ketsueki; 2022; 63(9):1052-1057. PubMed ID: 36198529
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapies for acute myeloid leukemia.
Stein EM
Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
[TBL] [Abstract][Full Text] [Related]
10. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
11. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
Hauge M; Bruserud Ø; Hatfield KJ
Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
[TBL] [Abstract][Full Text] [Related]
13. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Yang J; Schiffer CA
Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
[TBL] [Abstract][Full Text] [Related]
14. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
16. The most novel of the novel agents for acute myeloid leukemia.
Perl AE
Curr Opin Hematol; 2018 Mar; 25(2):81-89. PubMed ID: 29278535
[TBL] [Abstract][Full Text] [Related]
17. [Progress in molecularly targeted therapies for acute myeloid leukemia].
Tomita A
Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
19. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
20. New and emerging therapies for acute myeloid leukaemia.
Davis JR; Benjamin DJ; Jonas BA
J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]